AMLX
Amylyx Pharmaceuticals IncNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$1.51B
P/E Ratio
—
EPS
$-1.48
Beta
-0.10
52W High
$18.61
52W Low
$4.64
50-Day MA
$15.24
200-Day MA
$13.55
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
2.77
PEG Ratio
—
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company focused on developing groundbreaking therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Its flagship candidate, AMX0035, employs a unique neuroprotective mechanism that has shown potential in improving patient outcomes in ALS. With a robust clinical development pipeline and a team of experts in neurological disorders, Amylyx is well-positioned to tackle significant unmet medical needs, making it an attractive investment opportunity for institutional investors seeking exposure to advancements in therapeutic solutions for complex neurological conditions.
Fundamentals
| Revenue (TTM) | -665,000 |
| Gross Profit (TTM) | $-95.89M |
| EBITDA | $-158.80M |
| Operating Margin | 0.00% |
| Return on Equity | -63.30% |
| Return on Assets | -38.80% |
| Revenue/Share (TTM) | $-0.01 |
| Book Value | $2.46 |
| Price-to-Book | 5.53 |
| Price-to-Sales (TTM) | 0.66 |
| EV/Revenue | 6446.63 |
| EV/EBITDA | -11.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.60% |
| Shares Outstanding | $111.19M |
| Float | $83.53M |
| % Insiders | 7.91% |
| % Institutions | 105.09% |
Historical Volatility
HV 10-Day
56.68%
HV 20-Day
49.88%
HV 30-Day
47.42%
HV 60-Day
56.44%
HV Rank
3.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($23.40 target)
11
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026